Enzene is an end-to-end CDMO with services spanning discovery, development, and commercial supply, operating integrated sites in Pune (India) and New Jersey (USA). As a pioneer in next-generation biologics technologies, Enzene is disrupting the existing biologics manufacturing paradigm with its patented EnzeneX™ technology, which was the first fully-connected continuous manufacturing™ (FCCM™) platform validated for commercial biologics supply. We partner with innovators and biosimilar developers to deliver accelerated time-to-market, increased production yields, and cost reductions across a broad range of biologic modalities. Committed to pushing the boundaries of biologics manufacturing innovation, Enzene is striving to reduce monoclonal antibody production costs to below $40 per gram by 2025. Our microbial and mammalian drug substance plants, as well as our sterile fill & finish plant in India are EU-GMP certified. | Enzene is a leading global continuously innovative development and manufacturing organization (CIDMO). The company was founded on a belief that we have a responsibility to positively impact healthcare around the world by providing the technological expertise, passion for innovation, and dedication to helping clients bring accessible and affordable products to market. Built on a proven history of successful commercial launches and a strong early-stage product pipeline, Enzene continues to disrupt the CDMO industry with novel processes that improve quality and productivity while reducing costs and carbon footprint. Our comprehensive capabilities encompass R&D, analytics, and GMP manufacturing, empowering us to offer innovative, high-quality solutions that meet diverse client needs. By providing end-to-end CDMO services for biologics, from cell line development to fill & finish for complex molecules, we are a versatile CDMO partner for our clients across a wide array of modalities. And with multiple manufacturing lines at our Pune, India and New Jersey, USA facilities, Enzene is strategically positioned to meet the escalating demand for biologics and biosimilars across both hemispheres. Additionally, our proprietary continuous manufacturing technology, EnzeneX™, sets us apart as visionaries in the industry, driving healthcare advancement and setting new standards for biologics development and manufacturing. The EnzeneX™ platform optimizes quality, efficiency, and flexibility while supporting cost-effective, sustainable production of top-tier biologics, thereby improving global patient access. At Enzene, we are leaders who seek to solve today’s biotech challenges as well as tomorrow’s by upholding our core values of innovation, integrity, excellence, entrepreneurship, candor, and respect.
DNTOX GmbH
DNTOX has developed a test system that is able to evaluate compounds regarding their potential to disturb the human brain and its development in a fast and cost-efficient way, without animal testing. Thereby, DNTOX offers toxicological testing in vitro with a focus on developmental and adult neurotoxicity. This test system is comprised of a set of multicellular and multiplexed 2D/3D in vitro test methods that are based on human neural progenitor cells (hNPCs) and human induced pluripotent stem cells (hiPSCs). The toxicological evaluation is based on an in-house developed software combined with artificial intelligence. | DNTOX offers animal experiment-free toxicological testing services with a focus on developmental and adult neurotoxicity. By combining human cell-based 2D/3D test systems with state-of-the-art machine learning technology, DNTOX provides a faster, more cost-effective and more human-relevant alternative to traditionally used rodent studies. Next to regulatory purposes, these cost- and time-effective tests can be implemented as routine screening during the development of new chemicals and pharmaceuticals. Our innovative services facilitate the development of chemicals that are safe and sustainable by design and thereby contribute to the protection of customer health and the EU Chemicals Strategy for Sustainability Towards a Toxic-Free Environment.
Divamics Inc
Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to hunt new hits and PCCs in a more efficient and accurate way, especially for undrugable targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Our signature capacities include drug design for GPCR, allosteric sites, and PPI, transcription factors. Our targeting modalities cover small molecules, peptides, PROTAC, XDC, synthetic biology, and more. We have already collaborated with 25+ MNCs/bioteches to advance over 35 new drug development pipelines and achieved multiple breakthrough results. Our records include: *FIC Project: Pioneering Drug Development* 1. Proposed binding site hypotheses, enabling the creation of drugs from scratch 2. Identified hits within 30 syntheses in a FIC pipeline with no pre-existing clinical drugs *BIC Project: Revolutionizing Structural Optimization* 1. Combined SAR computational analysis with expert medicinal chemistry insights to innovate structural optimization 2. Achieved patent breakthrough and better potency within just 6 syntheses of peptides, currently in Phase II clinical trials; Phase II clinical trial data to be presented at the ADA Conference, June 2024 We want to find collaborators such as the early discovery departments of MNCs, biopharmaceuticals and biotechs, with flexible cooperation modes including strategic joint research and others. | Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to HUNT NEW LEADs and PCCs in a more efficient and accurate way, especially for UNDRUGGABLE targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Currently, we have 40+ partners (10 listed companies/MNCs, 2 USA biotechs) for 60 pipeline projects, while 2 of them have reached end of Phase Ⅲ. We work on strategic collaboration mode, or offer AI+DBDD services, based on our partners’ needs. | Divamics: Redefining the Speed of Precision Medicine Divamics is an AI-driven biotech leader accelerating the journey from hit identification to preclinical candidate (Hits-to-PCC). By integrating advanced AI with molecular dynamics, we provide biopharma partners with the clarity and confidence to make critical discovery decisions faster. With a proven track record of supporting 80+ pipelines for over 50 global partners, we have successfully reduced PCC discovery timelines to just 0.5 – 1.5 years. Our platform delivers unmatched precision across four key modalities: small molecules, peptides, antibodies, and nucleic acids.
Department for Business and Trade
The UK’s Department for Business and Trade supports international investment into the UK and UK businesses to grow and export. Whether you’re interested in clinical research for innovative products, working with the UK’s world-leading universities, SMEs and spin outs, leveraging our globally-unique datasets or manufacturing complex products at pace and scale, the UK has a strong offer spanning Northern Ireland, Scotland and Wales and would like to work with you. We are joined by 16 inspired, innovative and international UK co-exhibitors eager to connect with you. | Connect with the UK Invest in the UK: Access free, confidential advice and support on your inward investment journey. Buy from the UK: The UK’s thriving life sciences sector has a lot to offer the world, from innovative products to expert services. Export from the UK: We Provide insights, training, events, finance and expert support so exporters can realise the full benefits of internationalising. Innovate with the UK: Connect into our networks to partner with UK academia, research institutes, centres of excellent and spinouts. Talk to us today and continue connecting with the UK in your home country via our teams based in over 100 international markets. | This UK government department specialises in helping UK businesses and bringing investment into the UK.
DeepLife
DeepLife is a biotech company transforming drug development through artificial intelligence and digital twin technology. Our platform leverages an AI-driven engine that maps cell-type-specific networks, utilizing over 100 million harmonized single-cell omics data points to identify targets and analyze regulatory networks with unprecedented precision. Our modular platform rests on three pillars: a comprehensive data foundation, sophisticated target identification algorithms, and advanced drug repurposing capabilities. We deploy this technology both for our internal drug repurposing pipeline and for partner collaborations focusing on target identification, derisking assets, indication expansion, and disease relevance assessment. This approach dramatically accelerates development by finding new applications for compounds with established safety profiles. Supported by $10M Series A funding and strategic collaborations with partners like Beiersdorf on skin diseases and aging, DeepLife simulates drug effects at the cellular level, opening doors to novel therapies. Our AI-driven simulations and multi-omics analytics enable pharmaceutical partners to develop precision treatments that are more targeted, faster, and cost-effective in addressing complex medical challenges.
Decode Cure Limited
Decode Cure Limited specializes in rapid microbial identification using proprietary genomics and big data analytics for clinical, environmental, and research applications. Decode Cure’s mission is to reduce mortality rates and medical expenses associated with complex diseases by enabling faster and more accurate diagnoses. Our system can rapidly identify pathogens that cause respiratory tract illness, other complex human diseases, like cancer, Alzheimer’s disease and environmental issues. Decode Cure’s products have earned recognition and validation through respected external quality programs like College of American Pathologists and Quality Control for Molecular Diagnostics. Our solutions are instrumental in analyzing diverse samples for government, non-profit, and for-profit organizations, addressing critical health and environmental challenges.
Dairy Farmers of America
DFA is more than a Cooperative of dairy farm families — we’re a community of accountants, scientists, engineers, computer technicians, communicators and more. Whether you’ve stepped foot on a dairy farm or not, there’s a place at DFA for you to make your mark and help feed families down the road and across the world. At Dairy Farmers of America (DFA) we are #DFAProud to be a farmer-owned milk marketing cooperative. Dairy is what we do! Our mark matters and it represents the wholesomeness of dairy that we share with our communities and loved ones. Ready to make your mark? By joining DFA you can help us continue to make a difference that matters. We care deeply about the well-being of our neighbors and friends and we celebrate the diversity of our company and our world.
CURAVAC EUROPE
CuraVac is an innovative clinical stage company developing therapeutic vaccines to bring long lasting improvement to patients by addressing the root cause of autoimmune diseases. | CuraVac is a Belgian clinical-stage biotech developing Targeted Active Therapy (TAT) to neutralize harmful autoantibodies while preserving the immune system. Its lead candidate, CV-MG02, targets Myasthenia Gravis (MG), showing a strong safety profile and early efficacy in Phase 1. CuraVac is advancing an improved formulation to Phase 2 and expanding its platform to other autoimmune diseases, including MS, type 1 diabetes, SLE, Hashimoto’s disease, and Graves’ disease. CuraVac’s CV-MG02 is a Targeted Active Therapy (TAT) for Myasthenia Gravis (MG) that neutralizes disease-causing autoantibodies while preserving the immune system. Based on peptide antigens designed to induce the production of specific anti-autoantibodies that counteract autoimmune attack on the neuromuscular junction, CV-MG02 offers long-term efficacy with minimal dosing, reducing reliance on lifelong immunosuppression. Early trials showed a strong safety profile and sustained remission in some patients for years.
Cornell University, Center for Life Science Ventures & CAT
The Center for Life Science Ventures was founded in 2008 as a startup incubator to help develop young Cornell life science companies. The Center is funded through the Office of the Vice President for Research and Innovation, the Institute of Biotechnology and NYSTAR. The Center’s program focuses on accelerating research and development of its client’s companies’ technology and products, validating its client companies’ business plans, and strengthening their management teams. The Center’s goal is to facilitate the forward progress of client companies to the point where each will merit significant outside investment, and achieve self-sufficiency. In doing so, the Center for Life Science Ventures contributes to the University’s mission as New York State’s Morrill Land Grant institution to support local, regional, and state-wide Life Sciences jobs/economic development.
Concorde Battery Corp.
Concorde Batteries are installed as Original Equipment by the majority of aircraft manufacturers and used on military aircraft worldwide. Manufactured for over 40 years in West Covina, CA and Austell, GA Concorde’s unmatched performance is the result of Sealed Lead Acid Battery technology advanced by a team of dedicated engineers and skilled tradesmen to produce a battery providing superior starting power and maximum life. Visit our booth to learn about the batteries preferred by owners, operators, pilots, mechanics the world over. | Providing Original Equipment batteries to over 50 airframe manufacturers worldwide and certified batteries for hundreds of aircraft models, Concorde is your first choice for strong starts and durability. Concorde batteries have been adopted by militaries worldwide and offer more certified helicopter batteries than any other lead acid battery manufacturer. Batteries are available from Distributors globally www.concordebattery.com .